Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review
The clinical impact of Strongyloides stercoralis hyperinfection secondary to immunosuppressive therapy for coronavirus disease 2019 (COVID-19) has been an emerging topic of interest, although characteristics of Strongyloides infection in COVID-19 patients are not yet well characterized. This study s...
Gespeichert in:
Veröffentlicht in: | The American journal of tropical medicine and hygiene 2023-05, Vol.108 (5), p.901-905 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 905 |
---|---|
container_issue | 5 |
container_start_page | 901 |
container_title | The American journal of tropical medicine and hygiene |
container_volume | 108 |
creator | Tanariyakul, Manasawee Chang, Bolin Keitoku, Koichi Su, Marissa Hagiya, Hideharu Nishimura, Yoshito |
description | The clinical impact of Strongyloides stercoralis hyperinfection secondary to immunosuppressive therapy for coronavirus disease 2019 (COVID-19) has been an emerging topic of interest, although characteristics of Strongyloides infection in COVID-19 patients are not yet well characterized. This study summarizes the existing evidence of Strongyloides infection in COVID-19 patients and recommends future areas of research. According to the PRISMA Extension for Scoping Reviews, we performed a search on MEDLINE and EMBASE for articles with keywords including "Strongyloides," "Strongyloidiasis," and "COVID-19" from the inception of these databases to June 5, 2022. A total of 104 articles were found. After excluding duplication and thorough reviews, 11 articles, including two observational studies, one conference abstract, and nine case reports or series, were included. Two observational studies focused on revealing the prevalence of Strongyloides screening in COVID-19 patients and clinical follow-up. Among the included cases, patients were mostly from low- or middle-income countries and suffered from severe or critical COVID-19. Strongyloides hyperinfection and disseminated infection were reported in 60% and 20%, respectively. Interestingly, 40% did not have eosinophilia, a hallmark of parasitic infection, potentially leading to delay in diagnosis of strongyloidiasis. This systematic review summarizes the clinical characteristics of strongyloidiasis in COVID-19 infection. Although further studies to identify risks and precipitants associated with the onset of strongyloidiasis are crucial, increased awareness of the critical condition is warranted. |
doi_str_mv | 10.4269/ajtmh.22-0671 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10160902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789237094</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-1b9e755449de1c8ecc6f6cf59533029f0f1dd45960f91a2ff140a641cc79ecc13</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS0EotvCkSuyxIVLyozj2GsuCIUClSoVscDVch1716sk3tpO0f57sm2pgAunOcw3b-bNI-QFwilnQr0x2zJsThmrQEh8RBbIpahQ8OYxWQAAq5So5RE5znkLgEuG-JQc1UJxEEIsSNf2YQzW9LTdmGRscSnkEmym0dNVSXFc7_sYumByyLSbUhjXtGwcbS9_nH-oUNEvZuzcEOxbutrn4gYzT9OVjbsD-dXdBPfzGXniTZ_d8_t6Qr5_PPvWfq4uLj-dt-8vKss5LxVeKSebhnPVObRLZ63wwvpGNXUNTHnw2HW8UQK8QsO8Rw5GcLRWqhnG-oS8u9PdTVeD66wbSzK93qUwmLTX0QT9d2cMG72ONxoBBShgs8Lre4UUryeXix5Ctq7vzejilDWTS8VqCYrP6Kt_0G2c0jj702x-M5_15H8oRCZrdru2uqNsijkn5x9uRtCHmPVtzJoxfYh55l_-afSB_p1r_Qt1cqPx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2811273202</pqid></control><display><type>article</type><title>Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Tanariyakul, Manasawee ; Chang, Bolin ; Keitoku, Koichi ; Su, Marissa ; Hagiya, Hideharu ; Nishimura, Yoshito</creator><creatorcontrib>Tanariyakul, Manasawee ; Chang, Bolin ; Keitoku, Koichi ; Su, Marissa ; Hagiya, Hideharu ; Nishimura, Yoshito</creatorcontrib><description>The clinical impact of Strongyloides stercoralis hyperinfection secondary to immunosuppressive therapy for coronavirus disease 2019 (COVID-19) has been an emerging topic of interest, although characteristics of Strongyloides infection in COVID-19 patients are not yet well characterized. This study summarizes the existing evidence of Strongyloides infection in COVID-19 patients and recommends future areas of research. According to the PRISMA Extension for Scoping Reviews, we performed a search on MEDLINE and EMBASE for articles with keywords including "Strongyloides," "Strongyloidiasis," and "COVID-19" from the inception of these databases to June 5, 2022. A total of 104 articles were found. After excluding duplication and thorough reviews, 11 articles, including two observational studies, one conference abstract, and nine case reports or series, were included. Two observational studies focused on revealing the prevalence of Strongyloides screening in COVID-19 patients and clinical follow-up. Among the included cases, patients were mostly from low- or middle-income countries and suffered from severe or critical COVID-19. Strongyloides hyperinfection and disseminated infection were reported in 60% and 20%, respectively. Interestingly, 40% did not have eosinophilia, a hallmark of parasitic infection, potentially leading to delay in diagnosis of strongyloidiasis. This systematic review summarizes the clinical characteristics of strongyloidiasis in COVID-19 infection. Although further studies to identify risks and precipitants associated with the onset of strongyloidiasis are crucial, increased awareness of the critical condition is warranted.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.22-0671</identifier><identifier>PMID: 36940666</identifier><language>eng</language><publisher>United States: Institute of Tropical Medicine</publisher><subject>Animals ; Coronaviruses ; COVID-19 ; COVID-19 - complications ; COVID-19 - epidemiology ; Humans ; Immunosuppression Therapy ; Infections ; Observational studies ; Pandemics ; Parasitic diseases ; Strongyloides stercoralis ; Strongyloidiasis - drug therapy</subject><ispartof>The American journal of tropical medicine and hygiene, 2023-05, Vol.108 (5), p.901-905</ispartof><rights>Copyright Institute of Tropical Medicine May 2023</rights><rights>The author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-1b9e755449de1c8ecc6f6cf59533029f0f1dd45960f91a2ff140a641cc79ecc13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160902/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160902/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36940666$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanariyakul, Manasawee</creatorcontrib><creatorcontrib>Chang, Bolin</creatorcontrib><creatorcontrib>Keitoku, Koichi</creatorcontrib><creatorcontrib>Su, Marissa</creatorcontrib><creatorcontrib>Hagiya, Hideharu</creatorcontrib><creatorcontrib>Nishimura, Yoshito</creatorcontrib><title>Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>The clinical impact of Strongyloides stercoralis hyperinfection secondary to immunosuppressive therapy for coronavirus disease 2019 (COVID-19) has been an emerging topic of interest, although characteristics of Strongyloides infection in COVID-19 patients are not yet well characterized. This study summarizes the existing evidence of Strongyloides infection in COVID-19 patients and recommends future areas of research. According to the PRISMA Extension for Scoping Reviews, we performed a search on MEDLINE and EMBASE for articles with keywords including "Strongyloides," "Strongyloidiasis," and "COVID-19" from the inception of these databases to June 5, 2022. A total of 104 articles were found. After excluding duplication and thorough reviews, 11 articles, including two observational studies, one conference abstract, and nine case reports or series, were included. Two observational studies focused on revealing the prevalence of Strongyloides screening in COVID-19 patients and clinical follow-up. Among the included cases, patients were mostly from low- or middle-income countries and suffered from severe or critical COVID-19. Strongyloides hyperinfection and disseminated infection were reported in 60% and 20%, respectively. Interestingly, 40% did not have eosinophilia, a hallmark of parasitic infection, potentially leading to delay in diagnosis of strongyloidiasis. This systematic review summarizes the clinical characteristics of strongyloidiasis in COVID-19 infection. Although further studies to identify risks and precipitants associated with the onset of strongyloidiasis are crucial, increased awareness of the critical condition is warranted.</description><subject>Animals</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>Humans</subject><subject>Immunosuppression Therapy</subject><subject>Infections</subject><subject>Observational studies</subject><subject>Pandemics</subject><subject>Parasitic diseases</subject><subject>Strongyloides stercoralis</subject><subject>Strongyloidiasis - drug therapy</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFv1DAQhS0EotvCkSuyxIVLyozj2GsuCIUClSoVscDVch1716sk3tpO0f57sm2pgAunOcw3b-bNI-QFwilnQr0x2zJsThmrQEh8RBbIpahQ8OYxWQAAq5So5RE5znkLgEuG-JQc1UJxEEIsSNf2YQzW9LTdmGRscSnkEmym0dNVSXFc7_sYumByyLSbUhjXtGwcbS9_nH-oUNEvZuzcEOxbutrn4gYzT9OVjbsD-dXdBPfzGXniTZ_d8_t6Qr5_PPvWfq4uLj-dt-8vKss5LxVeKSebhnPVObRLZ63wwvpGNXUNTHnw2HW8UQK8QsO8Rw5GcLRWqhnG-oS8u9PdTVeD66wbSzK93qUwmLTX0QT9d2cMG72ONxoBBShgs8Lre4UUryeXix5Ctq7vzejilDWTS8VqCYrP6Kt_0G2c0jj702x-M5_15H8oRCZrdru2uqNsijkn5x9uRtCHmPVtzJoxfYh55l_-afSB_p1r_Qt1cqPx</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Tanariyakul, Manasawee</creator><creator>Chang, Bolin</creator><creator>Keitoku, Koichi</creator><creator>Su, Marissa</creator><creator>Hagiya, Hideharu</creator><creator>Nishimura, Yoshito</creator><general>Institute of Tropical Medicine</general><general>The American Society of Tropical Medicine and Hygiene</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230501</creationdate><title>Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review</title><author>Tanariyakul, Manasawee ; Chang, Bolin ; Keitoku, Koichi ; Su, Marissa ; Hagiya, Hideharu ; Nishimura, Yoshito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-1b9e755449de1c8ecc6f6cf59533029f0f1dd45960f91a2ff140a641cc79ecc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>Humans</topic><topic>Immunosuppression Therapy</topic><topic>Infections</topic><topic>Observational studies</topic><topic>Pandemics</topic><topic>Parasitic diseases</topic><topic>Strongyloides stercoralis</topic><topic>Strongyloidiasis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanariyakul, Manasawee</creatorcontrib><creatorcontrib>Chang, Bolin</creatorcontrib><creatorcontrib>Keitoku, Koichi</creatorcontrib><creatorcontrib>Su, Marissa</creatorcontrib><creatorcontrib>Hagiya, Hideharu</creatorcontrib><creatorcontrib>Nishimura, Yoshito</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanariyakul, Manasawee</au><au>Chang, Bolin</au><au>Keitoku, Koichi</au><au>Su, Marissa</au><au>Hagiya, Hideharu</au><au>Nishimura, Yoshito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>108</volume><issue>5</issue><spage>901</spage><epage>905</epage><pages>901-905</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><abstract>The clinical impact of Strongyloides stercoralis hyperinfection secondary to immunosuppressive therapy for coronavirus disease 2019 (COVID-19) has been an emerging topic of interest, although characteristics of Strongyloides infection in COVID-19 patients are not yet well characterized. This study summarizes the existing evidence of Strongyloides infection in COVID-19 patients and recommends future areas of research. According to the PRISMA Extension for Scoping Reviews, we performed a search on MEDLINE and EMBASE for articles with keywords including "Strongyloides," "Strongyloidiasis," and "COVID-19" from the inception of these databases to June 5, 2022. A total of 104 articles were found. After excluding duplication and thorough reviews, 11 articles, including two observational studies, one conference abstract, and nine case reports or series, were included. Two observational studies focused on revealing the prevalence of Strongyloides screening in COVID-19 patients and clinical follow-up. Among the included cases, patients were mostly from low- or middle-income countries and suffered from severe or critical COVID-19. Strongyloides hyperinfection and disseminated infection were reported in 60% and 20%, respectively. Interestingly, 40% did not have eosinophilia, a hallmark of parasitic infection, potentially leading to delay in diagnosis of strongyloidiasis. This systematic review summarizes the clinical characteristics of strongyloidiasis in COVID-19 infection. Although further studies to identify risks and precipitants associated with the onset of strongyloidiasis are crucial, increased awareness of the critical condition is warranted.</abstract><cop>United States</cop><pub>Institute of Tropical Medicine</pub><pmid>36940666</pmid><doi>10.4269/ajtmh.22-0671</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9637 |
ispartof | The American journal of tropical medicine and hygiene, 2023-05, Vol.108 (5), p.901-905 |
issn | 0002-9637 1476-1645 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10160902 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Animals Coronaviruses COVID-19 COVID-19 - complications COVID-19 - epidemiology Humans Immunosuppression Therapy Infections Observational studies Pandemics Parasitic diseases Strongyloides stercoralis Strongyloidiasis - drug therapy |
title | Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T04%3A00%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Characteristics%20of%20Strongyloidiasis%20during%20the%20COVID-19%20Pandemic:%20Systematic%20Scoping%20Review&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=Tanariyakul,%20Manasawee&rft.date=2023-05-01&rft.volume=108&rft.issue=5&rft.spage=901&rft.epage=905&rft.pages=901-905&rft.issn=0002-9637&rft.eissn=1476-1645&rft_id=info:doi/10.4269/ajtmh.22-0671&rft_dat=%3Cproquest_pubme%3E2789237094%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2811273202&rft_id=info:pmid/36940666&rfr_iscdi=true |